• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The controversy around anti-amyloid antibodies for treating Alzheimer's disease : The European Medical Agency's ruling against the latest anti-amyloid drugs highlights the ongoing debate about their safety and efficacy.围绕用于治疗阿尔茨海默病的抗淀粉样蛋白抗体的争议：欧洲药品管理局对最新抗淀粉样蛋白药物的裁决凸显了关于其安全性和有效性的持续争论。
EMBO Rep. 2024 Dec;25(12):5227-5231. doi: 10.1038/s44319-024-00294-4. Epub 2024 Oct 23.
2
A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer's disease.抗淀粉样蛋白β单克隆抗体治疗阿尔茨海默病的疗效和安全性的系统评价。
Expert Opin Biol Ther. 2024 Nov;24(11):1261-1269. doi: 10.1080/14712598.2024.2416947. Epub 2024 Nov 12.
3
Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities.阿杜卡奴单抗在阿尔茨海默病治疗中的作用：挑战与机遇。
Clin Interv Aging. 2022 May 18;17:797-810. doi: 10.2147/CIA.S325026. eCollection 2022.
4
At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact.照料者为早期阿尔茨海默病患者在家中进行甘特钠单抗给药：可行性、安全性和药效学影响。
J Prev Alzheimers Dis. 2024;11(3):537-548. doi: 10.14283/jpad.2024.60.
5
Aducanumab in Alzheimer's Disease: A Comparative Study of Its Effects on Dementia and Mild Cognitive Impairment.阿杜卡单抗治疗阿尔茨海默病：其对痴呆和轻度认知障碍影响的比较研究。
Cureus. 2024 Dec 17;16(12):e75907. doi: 10.7759/cureus.75907. eCollection 2024 Dec.
6
Anti-amyloid antibody treatments for Alzheimer's disease.用于治疗阿尔茨海默病的抗淀粉样蛋白抗体疗法。
Eur J Neurol. 2024 Feb;31(2):e16049. doi: 10.1111/ene.16049. Epub 2023 Sep 11.
7
Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise.抗淀粉样蛋白-β 单克隆抗体治疗阿尔茨海默病：陷阱与希望。
Biol Psychiatry. 2018 Feb 15;83(4):311-319. doi: 10.1016/j.biopsych.2017.08.010. Epub 2017 Aug 24.
8
Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review.新型抗淀粉样蛋白-β（Aβ）单克隆抗体 Lecanemab 治疗阿尔茨海默病的系统评价。
Int J Immunopathol Pharmacol. 2023 Jan-Dec;37:3946320231209839. doi: 10.1177/03946320231209839.
9
Ameliorating effect of anti-Alzheimer's drugs on the bidirectional association between type 2 diabetes mellitus and Alzheimer's disease.抗阿尔茨海默病药物对2型糖尿病与阿尔茨海默病双向关联的改善作用。
Exp Biol Med (Maywood). 2017 Jul;242(13):1335-1344. doi: 10.1177/1535370217711440. Epub 2017 May 23.
10
High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects.阿尔茨海默病中的高清除率抗淀粉样蛋白免疫疗法。第1部分：疗效和安全性数据的荟萃分析与综述以及医学经济学方面
Rev Neurol (Paris). 2022 Dec;178(10):1011-1030. doi: 10.1016/j.neurol.2022.06.012. Epub 2022 Sep 29.

引用本文的文献

1
From Better Diagnostics to Earlier Treatment: The Rapidly Evolving Alzheimer's Disease Landscape.从更好的诊断到更早的治疗：快速演变的阿尔茨海默病格局
Medicina (Kaunas). 2025 Aug 14;61(8):1462. doi: 10.3390/medicina61081462.
2
Neuroprotective Effects of Dehydroepiandrosterone Sulphate Against Aβ Toxicity and Accumulation in Cellular and Animal Model of Alzheimer's Disease.硫酸脱氢表雄酮对阿尔茨海默病细胞和动物模型中β淀粉样蛋白毒性及蓄积的神经保护作用
Biomedicines. 2025 Feb 11;13(2):432. doi: 10.3390/biomedicines13020432.

本文引用的文献

1
Increases in amyloid-β42 slow cognitive and clinical decline in Alzheimer's disease trials.淀粉样蛋白-β42 的增加减缓了阿尔茨海默病试验中的认知和临床衰退。
Brain. 2024 Oct 3;147(10):3513-3521. doi: 10.1093/brain/awae216.
2
Lecanemab and Donanemab as Therapies for Alzheimer's Disease: An Illustrated Perspective on the Data.莱卡奈单抗和多奈单抗治疗阿尔茨海默病：数据的图解视角
eNeuro. 2024 Jul 1;11(7). doi: 10.1523/ENEURO.0319-23.2024. Print 2024 Jul.
3
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.修订的阿尔茨海默病诊断和分期标准：阿尔茨海默病协会工作组。
Alzheimers Dement. 2024 Aug;20(8):5143-5169. doi: 10.1002/alz.13859. Epub 2024 Jun 27.
4
Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.治疗阿尔茨海默病患者认知能力下降的单克隆抗体的疗效和安全性比较：系统评价和网络荟萃分析。
CNS Drugs. 2024 Mar;38(3):169-192. doi: 10.1007/s40263-024-01067-2. Epub 2024 Mar 1.
5
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
6
Severity Distribution of Alzheimer's Disease Dementia and Mild Cognitive Impairment in the Framingham Heart Study.弗雷明汉心脏研究中阿尔茨海默病痴呆和轻度认知障碍的严重程度分布。
J Alzheimers Dis. 2021;79(2):807-817. doi: 10.3233/JAD-200786.
7
Donepezil for dementia due to Alzheimer's disease.多奈哌齐用于治疗阿尔茨海默病所致的痴呆。
Cochrane Database Syst Rev. 2018 Jun 18;6(6):CD001190. doi: 10.1002/14651858.CD001190.pub3.
8
Donepezil for dementia due to Alzheimer's disease.多奈哌齐用于治疗阿尔茨海默病所致痴呆。
Cochrane Database Syst Rev. 2003(3):CD001190. doi: 10.1002/14651858.CD001190.
9
Alzheimer's disease: the amyloid cascade hypothesis.阿尔茨海默病：淀粉样蛋白级联假说
Science. 1992 Apr 10;256(5054):184-5. doi: 10.1126/science.1566067.

围绕用于治疗阿尔茨海默病的抗淀粉样蛋白抗体的争议：欧洲药品管理局对最新抗淀粉样蛋白药物的裁决凸显了关于其安全性和有效性的持续争论。

The controversy around anti-amyloid antibodies for treating Alzheimer's disease : The European Medical Agency's ruling against the latest anti-amyloid drugs highlights the ongoing debate about their safety and efficacy.

作者信息

Hunter Philip

机构信息

Freelance Journalist, London, UK.

出版信息

EMBO Rep. 2024 Dec;25(12):5227-5231. doi: 10.1038/s44319-024-00294-4. Epub 2024 Oct 23.

DOI:10.1038/s44319-024-00294-4
PMID:39443750
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11624191/
Abstract

The recent rejection of lecanemab by the European Medicines Agency despite its approval in other countries highlights the debate among researchers and regulatory bodies about the efficacy, safety, and underlying scientific basis of drugs to treat Alzheimer’s disease. [Image: see text]

摘要

尽管lecanemab在其他国家已获批准，但欧洲药品管理局最近拒绝了它，这凸显了研究人员和监管机构之间关于治疗阿尔茨海默病药物的疗效、安全性及潜在科学依据的争论。[图片：见正文]